About Evoxx Technologies
Evoxx Technologies is a company based in Monheim Am Rhein (Germany) founded in 2006 was acquired by Advanced Enzyme Technologies in July 2017. The company has 15 employees. Evoxx Technologies offers products and services including Food Processing Enzymes, Biocatalysis Enzymes, and Human Nutrition Enzymes. Evoxx Technologies operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Monheim Am Rhein, Germany
- Employees 15
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website evoxx.com
- Social LinkedIn
- Acquired by Advanced Enzyme Technologies (Jul 2017)
- Legal Name Evoxx Technologies Gmbh
- Latest Funding Round$553.8K (USD), Grant
Apr 2015
- InvestorsAdvanced Enzyme Technologies
& 2 more
- Employee Count15
- Acquired byAdvanced Enzyme Technologies
(Jul 2017)
Products & Services of Evoxx Technologies
Evoxx Technologies offers a comprehensive portfolio of products and services, including Food Processing Enzymes, Biocatalysis Enzymes, and Human Nutrition Enzymes.
Enzymes used for processing food products efficiently
Enzymes for chemical and pharma production processes
Enzymes as active ingredients in pharmaceutical formulations
Funding Insights of Evoxx Technologies
- Total Rounds 3
- Last Round Grant — $553,799
- Investors Count 2
All 3 funding rounds of Evoxx Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2015 | $553,799 | Grant | – | – | |
| Jan 2015 | $553,799 | Grant | – | – | |
| Aug 2007 | – | Seed | – | HTGF | – |
3 investors in total: 3 institutional.
Investors in Evoxx Technologies
Evoxx Technologies has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Advanced Enzyme Technologies, European Union and High-Tech Gründerfonds.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments are made in high-tech startups by HTGF. | – | htgf.de | Bonn, Germany | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Enzymes are manufactured for nutrition, food, feed, and textile industries. | 1989 | advancedenzymes.com | Thane, India |
Investor details for Evoxx Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Evoxx Technologies
4 dated milestones of Evoxx Technologies across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Evoxx Technologies is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $554K.
- Exit Acquired by Advanced Enzyme Technologies.
Competitors of Evoxx Technologies
Evoxx Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Evoxx Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evoxx Technologies
The website of Evoxx Technologies (evoxx.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 46.4% vs previous month
Latest news on Evoxx Technologies
Complete news archive for Evoxx Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Evoxx Technologies
10 companies that operate in the same segment as Evoxx Technologies (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Evoxx Technologies
Evoxx Technologies was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Evoxx Technologies is headquartered in Monheim Am Rhein, Germany. It is registered at Monheim Am Rhein, Nordrhein-westfalen, Germany.
Evoxx Technologies has 15 employees.
Evoxx Technologies was established in 2006 as a spin-off from the Institute of Molecular Enzyme Technology at Heinrich-Heine University in Dusseldorf and Forschungszentrum Julich. Enzymes and biocatalytic processes are developed for the chemical and pharmaceutical sectors. A range of enzymes and customized bio-catalysts is provided for applications including textiles, adhesives, nutrition, and refinement processes. Laboratories adhere to S1 and S2 standards, with development scaled to commercial levels in Germany.
Evoxx Technologies's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Evoxx Technologies offers Food Processing Enzymes, Biocatalysis Enzymes, and Human Nutrition Enzymes.
Evoxx Technologies has 3 investors. Key investors include Advanced Enzyme Technologies, European Union, and High-Tech Gründerfonds.
Evoxx Technologies operates through Evoxx Technologies Gmbh.
Yes. Evoxx Technologies was acquired by Advanced Enzyme Technologies in July 2017.